Gut microbiota drug biotransformation as a tool to unravel the mechanisms of metabolic microbiota-host interactions
This project aims to systematically study metabolic interactions between gut microbiota and hosts using drug biotransformation to improve understanding of microbiome-related health variations and drug responses.
Projectdetails
Introduction
The variability of the human gut microbiome (the entirety of microorganisms inhabiting the intestine) far exceeds human genome variability and has been connected to various aspects of human health. Although microbiome differences are often linked to altered metabolism, the current view on metabolic interactions between the microbiota and the host remains mostly descriptive due to several limiting factors.
Limitations in Current Research
- Correlative Analyses: Most sequencing-based human microbiome studies rely on correlative analyses between microbiome composition and human phenotypes.
- Incomplete Genome Annotations: These studies depend on largely incomplete microbial genome annotations and are not targeted to identify community-mediated functional traits.
- Metabolite Origins: Many metabolites can be both of microbial and human origin, making it conceptually and methodologically challenging to disentangle metabolic microbiota-host interactions.
Proposed Strategy
To overcome these limitations, I propose a systematic bottom-up strategy to mechanistically study metabolic microbiota-host interactions by harnessing the gut microbiota’s capacity to biotransform (chemically modify) drug molecules.
Rationale for Using Medical Drugs
The large chemical diversity and exogenous origin of medical drugs make them ideally suited for experimental in vitro and in vivo approaches to probe microbiota-host interactions in a controlled way.
Methodology
We will combine the following approaches:
- High-throughput culturing protocols
- Genetics
- Metabolomics measurements
- Genomics analyses
- Gnotobiotic mouse work
- Computational modeling
This combination aims to connect interpersonal differences in microbiome composition to differences in metabolic functions of individuals’ gut microbiota and ultimately link them to molecular host phenotypes.
Importance of the Project
Generating these mechanistic insights and transformational resources is essential to understand the fundamental principles of the microbiota-host relationship.
Medical Relevance
In addition, this project has direct medical relevance, as it provides actionable microbiome-based links to interpersonal differences in medical drug response, which remain a widespread problem in clinical practice.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.894.858 |
Totale projectbegroting | € 1.894.858 |
Tijdlijn
Startdatum | 1-5-2023 |
Einddatum | 30-4-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- EUROPEAN MOLECULAR BIOLOGY LABORATORYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Resolving metabolic interactions between the gut microbiota and the host with multi-omics-based modellingThis project aims to systematically characterize gut bacteria interactions and their metabolic contributions to host health using experimental and computational methods, enabling targeted microbiota interventions. | ERC Starting... | € 1.499.323 | 2024 | Details |
Proteome-wide Functional Interrogation and Modulation of Gut Microbiome SpeciesThis project aims to identify and manipulate gut microbiome protein functions using high-throughput proteomics to develop targeted therapies for restoring microbial health. | ERC Starting... | € 1.499.980 | 2023 | Details |
Gut microbiome-mediated activities of psychotropic drugsThis project aims to explore the role of gut microbiomes in the efficacy and side effects of psychotropic drugs, potentially revolutionizing personalized drug therapy for mental illnesses. | ERC Starting... | € 1.497.033 | 2024 | Details |
Microbial ecosystems biology in the human gutThis project aims to develop a comprehensive ecosystem model of child gut microbiota using multiomic data to predict and manipulate microbial responses for improved health interventions. | ERC Starting... | € 1.485.413 | 2023 | Details |
Dissection of the host-microbe crosstalk that controls metabolism and physiology in intestinal symbiosisThis project aims to explore the regulatory mechanisms of intestinal bacteria and their symbiotic relationship with hosts using Drosophila to enhance understanding of gut metabolism and health. | ERC Starting... | € 1.499.600 | 2023 | Details |
Resolving metabolic interactions between the gut microbiota and the host with multi-omics-based modelling
This project aims to systematically characterize gut bacteria interactions and their metabolic contributions to host health using experimental and computational methods, enabling targeted microbiota interventions.
Proteome-wide Functional Interrogation and Modulation of Gut Microbiome Species
This project aims to identify and manipulate gut microbiome protein functions using high-throughput proteomics to develop targeted therapies for restoring microbial health.
Gut microbiome-mediated activities of psychotropic drugs
This project aims to explore the role of gut microbiomes in the efficacy and side effects of psychotropic drugs, potentially revolutionizing personalized drug therapy for mental illnesses.
Microbial ecosystems biology in the human gut
This project aims to develop a comprehensive ecosystem model of child gut microbiota using multiomic data to predict and manipulate microbial responses for improved health interventions.
Dissection of the host-microbe crosstalk that controls metabolism and physiology in intestinal symbiosis
This project aims to explore the regulatory mechanisms of intestinal bacteria and their symbiotic relationship with hosts using Drosophila to enhance understanding of gut metabolism and health.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
MicroBioDx: karakterisatie van microbioom-gastheer interactiesTenWise en Predica ontwikkelen de MicroBioD om de complexe samenstelling van micro-organismen te analyseren en gerichte behandelingen voor dysbiose te faciliteren. | Mkb-innovati... | € 143.080 | 2021 | Details |
MicroBioDx: karakterisatie van microbioom-gastheer interacties
TenWise en Predica ontwikkelen de MicroBioD om de complexe samenstelling van micro-organismen te analyseren en gerichte behandelingen voor dysbiose te faciliteren.